Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients - Report of six cases

C. Socci, L. Falqui, A. M. Davalli, Camillo Ricordi, S. Braghi, F. Bertuzzi, P. Maffi, A. Secchi, F. Gavazzi, M. Freschi, P. Magistretti, S. Socci, A. Vignali, V. Di Carlo, G. Pozza

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The aim of this study was to evaluate the feasibility of islet allografts in patients with type 1 diabetes melititus. Six patients received human islets from either one or two donors via the portal vein, after (n=4) or simultaneously with (n=2) a kidney graft. The patients with functioning kidney grafts (nos. 1-4) were already on triple immunosuppressive therapy (cyclosporine A, azathioprine, prednisone). Prednisone was increased to 60 mg/day for 15 days after the islet transplant in patient 1. Patient 2-4 and the patients who underwent a simultaneous kidney-islets graft (nos. 5, 6) also received antilymphocyte globulin. Intravenous insulin was given for the first 15 days to maintain blood glucose concentrations within the normal range. Patient 1 rejected the islets within 15 days of islet transplantation. In patient 2, a 25% reduction in insulin requirement was observed and 12 months after transplantation post-prandial serum C-peptide was 1.5 ng/ml. In patient 3, the insulin requirement decreased from 40 to 8 units/day with a post-prandial serum C-peptide of 4.1 ng/ml 12 months after islet transplantation. In patient 4 the post-prandial secretion of C-peptide increased to 6.4 ng/ml. Six months after the islet infusion, insulin therapy was discontinued and HbA1c, 24-h metabolic profile and oral glucose tolerance test remained within the normal range. He had remained off insulin for 5 months until recently, when foot gangrene paralleled a worsening of post-prandial glycaemic control. Twelve months after transplantation he is receiving 8 units insulin/day. Patients 5 and 6 received a simultaneous kidney and islet graft and 6 months after transplantation their post-prandial C-peptide secretion peaks were 2.5 and 1.9 ng/ml respectively. Their daily insulin requirement was not significantly modified. In conclusion, these results show that an adequate number of human islets injected intraportally in type 1 diabetic patients can replace the pancreatic endocrine function and can lead to insulin independence.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalActa Diabetologica
Volume28
Issue number2
DOIs
StatePublished - Jun 1 1991
Externally publishedYes

Fingerprint

Islets of Langerhans Transplantation
Insulin
C-Peptide
Meals
Transplants
Kidney
Transplantation
Prednisone
Reference Values
Gangrene
Antilymphocyte Serum
Metabolome
Azathioprine
Immunosuppressive Agents
Glucose Tolerance Test
Portal Vein
Serum
Type 1 Diabetes Mellitus
Cyclosporine
Allografts

Keywords

  • Human
  • insulin-dependent diabetes mellitus
  • Islet allograft
  • Type 1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients - Report of six cases. / Socci, C.; Falqui, L.; Davalli, A. M.; Ricordi, Camillo; Braghi, S.; Bertuzzi, F.; Maffi, P.; Secchi, A.; Gavazzi, F.; Freschi, M.; Magistretti, P.; Socci, S.; Vignali, A.; Di Carlo, V.; Pozza, G.

In: Acta Diabetologica, Vol. 28, No. 2, 01.06.1991, p. 151-157.

Research output: Contribution to journalArticle

Socci, C, Falqui, L, Davalli, AM, Ricordi, C, Braghi, S, Bertuzzi, F, Maffi, P, Secchi, A, Gavazzi, F, Freschi, M, Magistretti, P, Socci, S, Vignali, A, Di Carlo, V & Pozza, G 1991, 'Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients - Report of six cases', Acta Diabetologica, vol. 28, no. 2, pp. 151-157. https://doi.org/10.1007/BF00579718
Socci, C. ; Falqui, L. ; Davalli, A. M. ; Ricordi, Camillo ; Braghi, S. ; Bertuzzi, F. ; Maffi, P. ; Secchi, A. ; Gavazzi, F. ; Freschi, M. ; Magistretti, P. ; Socci, S. ; Vignali, A. ; Di Carlo, V. ; Pozza, G. / Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients - Report of six cases. In: Acta Diabetologica. 1991 ; Vol. 28, No. 2. pp. 151-157.
@article{ddeb7740799a46b8bf679fd589d58ed9,
title = "Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients - Report of six cases",
abstract = "The aim of this study was to evaluate the feasibility of islet allografts in patients with type 1 diabetes melititus. Six patients received human islets from either one or two donors via the portal vein, after (n=4) or simultaneously with (n=2) a kidney graft. The patients with functioning kidney grafts (nos. 1-4) were already on triple immunosuppressive therapy (cyclosporine A, azathioprine, prednisone). Prednisone was increased to 60 mg/day for 15 days after the islet transplant in patient 1. Patient 2-4 and the patients who underwent a simultaneous kidney-islets graft (nos. 5, 6) also received antilymphocyte globulin. Intravenous insulin was given for the first 15 days to maintain blood glucose concentrations within the normal range. Patient 1 rejected the islets within 15 days of islet transplantation. In patient 2, a 25{\%} reduction in insulin requirement was observed and 12 months after transplantation post-prandial serum C-peptide was 1.5 ng/ml. In patient 3, the insulin requirement decreased from 40 to 8 units/day with a post-prandial serum C-peptide of 4.1 ng/ml 12 months after islet transplantation. In patient 4 the post-prandial secretion of C-peptide increased to 6.4 ng/ml. Six months after the islet infusion, insulin therapy was discontinued and HbA1c, 24-h metabolic profile and oral glucose tolerance test remained within the normal range. He had remained off insulin for 5 months until recently, when foot gangrene paralleled a worsening of post-prandial glycaemic control. Twelve months after transplantation he is receiving 8 units insulin/day. Patients 5 and 6 received a simultaneous kidney and islet graft and 6 months after transplantation their post-prandial C-peptide secretion peaks were 2.5 and 1.9 ng/ml respectively. Their daily insulin requirement was not significantly modified. In conclusion, these results show that an adequate number of human islets injected intraportally in type 1 diabetic patients can replace the pancreatic endocrine function and can lead to insulin independence.",
keywords = "Human, insulin-dependent diabetes mellitus, Islet allograft, Type 1",
author = "C. Socci and L. Falqui and Davalli, {A. M.} and Camillo Ricordi and S. Braghi and F. Bertuzzi and P. Maffi and A. Secchi and F. Gavazzi and M. Freschi and P. Magistretti and S. Socci and A. Vignali and {Di Carlo}, V. and G. Pozza",
year = "1991",
month = "6",
day = "1",
doi = "10.1007/BF00579718",
language = "English",
volume = "28",
pages = "151--157",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Casa Editrice II Ponte",
number = "2",

}

TY - JOUR

T1 - Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients - Report of six cases

AU - Socci, C.

AU - Falqui, L.

AU - Davalli, A. M.

AU - Ricordi, Camillo

AU - Braghi, S.

AU - Bertuzzi, F.

AU - Maffi, P.

AU - Secchi, A.

AU - Gavazzi, F.

AU - Freschi, M.

AU - Magistretti, P.

AU - Socci, S.

AU - Vignali, A.

AU - Di Carlo, V.

AU - Pozza, G.

PY - 1991/6/1

Y1 - 1991/6/1

N2 - The aim of this study was to evaluate the feasibility of islet allografts in patients with type 1 diabetes melititus. Six patients received human islets from either one or two donors via the portal vein, after (n=4) or simultaneously with (n=2) a kidney graft. The patients with functioning kidney grafts (nos. 1-4) were already on triple immunosuppressive therapy (cyclosporine A, azathioprine, prednisone). Prednisone was increased to 60 mg/day for 15 days after the islet transplant in patient 1. Patient 2-4 and the patients who underwent a simultaneous kidney-islets graft (nos. 5, 6) also received antilymphocyte globulin. Intravenous insulin was given for the first 15 days to maintain blood glucose concentrations within the normal range. Patient 1 rejected the islets within 15 days of islet transplantation. In patient 2, a 25% reduction in insulin requirement was observed and 12 months after transplantation post-prandial serum C-peptide was 1.5 ng/ml. In patient 3, the insulin requirement decreased from 40 to 8 units/day with a post-prandial serum C-peptide of 4.1 ng/ml 12 months after islet transplantation. In patient 4 the post-prandial secretion of C-peptide increased to 6.4 ng/ml. Six months after the islet infusion, insulin therapy was discontinued and HbA1c, 24-h metabolic profile and oral glucose tolerance test remained within the normal range. He had remained off insulin for 5 months until recently, when foot gangrene paralleled a worsening of post-prandial glycaemic control. Twelve months after transplantation he is receiving 8 units insulin/day. Patients 5 and 6 received a simultaneous kidney and islet graft and 6 months after transplantation their post-prandial C-peptide secretion peaks were 2.5 and 1.9 ng/ml respectively. Their daily insulin requirement was not significantly modified. In conclusion, these results show that an adequate number of human islets injected intraportally in type 1 diabetic patients can replace the pancreatic endocrine function and can lead to insulin independence.

AB - The aim of this study was to evaluate the feasibility of islet allografts in patients with type 1 diabetes melititus. Six patients received human islets from either one or two donors via the portal vein, after (n=4) or simultaneously with (n=2) a kidney graft. The patients with functioning kidney grafts (nos. 1-4) were already on triple immunosuppressive therapy (cyclosporine A, azathioprine, prednisone). Prednisone was increased to 60 mg/day for 15 days after the islet transplant in patient 1. Patient 2-4 and the patients who underwent a simultaneous kidney-islets graft (nos. 5, 6) also received antilymphocyte globulin. Intravenous insulin was given for the first 15 days to maintain blood glucose concentrations within the normal range. Patient 1 rejected the islets within 15 days of islet transplantation. In patient 2, a 25% reduction in insulin requirement was observed and 12 months after transplantation post-prandial serum C-peptide was 1.5 ng/ml. In patient 3, the insulin requirement decreased from 40 to 8 units/day with a post-prandial serum C-peptide of 4.1 ng/ml 12 months after islet transplantation. In patient 4 the post-prandial secretion of C-peptide increased to 6.4 ng/ml. Six months after the islet infusion, insulin therapy was discontinued and HbA1c, 24-h metabolic profile and oral glucose tolerance test remained within the normal range. He had remained off insulin for 5 months until recently, when foot gangrene paralleled a worsening of post-prandial glycaemic control. Twelve months after transplantation he is receiving 8 units insulin/day. Patients 5 and 6 received a simultaneous kidney and islet graft and 6 months after transplantation their post-prandial C-peptide secretion peaks were 2.5 and 1.9 ng/ml respectively. Their daily insulin requirement was not significantly modified. In conclusion, these results show that an adequate number of human islets injected intraportally in type 1 diabetic patients can replace the pancreatic endocrine function and can lead to insulin independence.

KW - Human

KW - insulin-dependent diabetes mellitus

KW - Islet allograft

KW - Type 1

UR - http://www.scopus.com/inward/record.url?scp=0026293707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026293707&partnerID=8YFLogxK

U2 - 10.1007/BF00579718

DO - 10.1007/BF00579718

M3 - Article

C2 - 1777651

AN - SCOPUS:0026293707

VL - 28

SP - 151

EP - 157

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 2

ER -